LONDON--(BUSINESS WIRE)--BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that the current Chief Technology Officer (CTO), Dr. Daniel Neil, is leaving the Company at the beginning of April after 7 years at BenevolentAI to relocate to be nearer his family.

伦敦--（商业新闻短讯）--BenevolentAI（“BenevolentAI”或“公司”）（阿姆斯特丹泛欧交易所：BAI）是应用先进人工智能加速生物制药药物发现的领导者，今天宣布，现任首席技术官（CTO）丹尼尔·尼尔博士在BenevolentAI工作了7年后，将于4月初离开公司，搬到离家人更近的地方。

The Company is pleased to announce the appointment of Dr. James Malone as BenevolentAI’s new Chief Technology Officer. James will join at the beginning of April and will be based out of the UK, reporting into BenevolentAI’s CEO, Dr. Joerg Moeller..

公司很高兴宣布任命JamesMalone博士为BenevolentAI的新首席技术官。James将于4月初加入，并将常驻英国，向BenevolentAI的首席执行官Joerg Moeller博士汇报。。

James has over 20 years’ experience in industry and academia, working across data engineering, AI and bioinformatics, as well as building and leading global engineering teams, largely to support biomedical R&D. Prior to joining BenevolentAI, James was Vice President of Engineering at Logically.ai and previously held senior leadership roles at AI life sciences companies BenchSci and SciBite..

詹姆斯在工业界和学术界拥有20多年的经验，在数据工程、人工智能和生物信息学领域工作，并建立和领导全球工程团队，主要支持生物医学研发。在加入BenevolentAI之前，詹姆斯曾任Logical.AI工程副总裁，并曾在AI生命科学公司BenchSci和SciBite担任高级领导职务。。

At BenchSci, as VP Data Engineering, Machine Learning and Bioinformatics, he was involved in applying best practices in AI and data engineering into R&D, including drug safety and discovery. As Chief Technology Officer at SciBite, James helped build software using ontologies, machine learning and knowledge graphs to analyse scientific data.

在BenchSci担任数据工程、机器学习和生物信息学副总裁，他参与将人工智能和数据工程的最佳实践应用于研发，包括药物安全和发现。作为SciBite的首席技术官，詹姆斯帮助构建了使用本体论、机器学习和知识图来分析科学数据的软件。

Prior to this he was at the European BioInformatics Institute (EBI) working on a variety of data sources, such as Open Targets..

在此之前，他在欧洲生物信息学研究所（EBI）研究各种数据源，例如开放目标。。

James has a PhD in Machine Learning and Bioinformatics and spent two years at Edinburgh University as a Research Fellow in Artificial Intelligence.

詹姆斯拥有机器学习和生物信息学博士学位，曾在爱丁堡大学担任人工智能研究员两年。

Dr. Joerg Moeller, Chief Executive Officer of BenevolentAI, commented: “On behalf of BenevolentAI, I want to thank Daniel Neil for his many achievements and dedication to the Company over many years and wish him well for the future. We are excited to welcome James Malone to BenevolentAI as our new CTO.

BenevolentAI首席执行官Joerg Moeller博士评论道：“我代表BenevolentAI感谢Daniel Neil多年来取得的成就和对公司的奉献，并祝他未来一切顺利。我们很高兴欢迎James Malone担任BenevolentAI的新首席技术官。

James’ extensive experience is aligned to the problems of drug discovery and development and AI approaches. Specifically, his experience in building technology to support R&D within biotech will help with the continuing development of the BenevolentAI PlatformTM, which is critical for us to deliver cutting edge AI-driven drug discovery.”.

詹姆斯的丰富经验与药物发现和开发以及人工智能方法的问题相一致。具体而言，他在构建技术以支持生物技术研发方面的经验将有助于BenevolentAI PlatformTM的持续发展，这对于我们提供先进的人工智能驱动的药物发现至关重要。”。

Dr. James Malone, incoming Chief Technology Officer, commented: “I’m excited to join the leadership team at BenevolentAI. I believe the combination of the Benevolent PlatformTM, along with the Company’s in-house scientific expertise, gives BenevolentAI strong foundations to continue to advance the use of AI in drug discovery and development to find life-changing treatments for patients.”.

即将上任的首席技术官詹姆斯·马龙博士评论道：“我很高兴加入BenevolentAI的领导团队。我相信BenevolentAI平台TM与公司内部的科学专业知识相结合，为BenevolentAI继续推进人工智能在药物发现和开发中的应用，为患者找到改变生活的治疗方法奠定了坚实的基础。”。

About BenevolentAI

关于慈善AI

At BenevolentAI (AMS: BAI), we serve patients by leveraging our proprietary and validated Benevolent PlatformTM that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery..

在BenevolentAI（AMS:BAI），我们通过利用我们专有且经过验证的Benevolent PlatformTM为患者提供服务，该平台整合了人工智能和科学，以发现新的生物学，预测新的靶标，并开发一流或一流的复杂疾病药物。通过应用专有的先进人工智能工具，结合内部科学专业知识和湿实验室设施，BenevolentAI在识别和加速新药发现方面处于有利地位。。

The Company’s business model presents multiple routes for value creation including discovery collaborations with pharma companies like AstraZeneca and Merck, advancing in-house pipelines to inflection points, and commercialising a suite of knowledge exploration tools. Headquartered in London, with wet labs in Cambridge (UK) and an office in New York, BenevolentAI is at the forefront of reshaping the future of drug discovery and delivering innovative medicines..

该公司的商业模式为价值创造提供了多种途径，包括与阿斯利康（AstraZeneca）和默克（Merck）等制药公司的发现合作，将内部管道推进到拐点，以及将一套知识探索工具商业化。BenevolentAI总部位于伦敦，在剑桥（英国）设有wet实验室，在纽约设有办事处，在重塑药物发现的未来和提供创新药物方面处于领先地位。。

Category: Non-regulatory

类别：非监管